Value Investing Firm GREAT POINT PARTNERS Makes Strategic Biopharmaceutical Acquisition in Inventiva SA

Great Point Partners LLC has acquired 10,576,827 shares in Inventiva SA, marking a significant investment in the biopharmaceutical sector. This transaction represents a 16.49% impact on the firm's portfolio, with shares now constituting 7.42% of its total holdings. Inventiva SA is a France-based biopharmaceutical company focused on developing drugs for non-alcoholic steatohepatitis (NASH), with a market capitalization of $435.32 million. The company's current stock price stands at $3.13, with a GF Value of $2.75, indicating modest overvaluation.